Business Context and Reporting Period
This Form 8-K, dated March 14, 2024, reports on AgeX Therapeutics, Inc. (the "Registrant") and its proposed merger with Serina Therapeutics, Inc. The filing details the results of a special meeting of stockholders held on March 14, 2024, where shareholders approved a reverse stock split and the terms of the merger agreement. Upon completion of the merger, the combined entity will be renamed "Serina Therapeutics, Inc."
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period. Key capital structure metrics include:
- Reverse Stock Split: Approved at a ratio of 1-for-35.17, effective March 14, 2024, at 10:00 a.m. Eastern Time.
- Share Count: 87,951,260 shares were outstanding as of the record date (February 13, 2024). Post-split, the company targeted approximately 2,500,000 shares outstanding prior to the merger.
- Trading Symbol: The combined company is expected to trade under the ticker "SER" on the NYSE American starting March 27, 2024.
- Authorized Stock: Shareholders approved the issuance of 40,000,000 shares of common stock and 5,000,000 shares of preferred stock for the combined company.
Material Changes and Voting Results
Shareholders voted on six proposals related to the merger and corporate governance. All proposals were approved. The voting results for the primary proposals were:
- Proposal 1 (Merger Approval): 69,047,139 votes For; 6,646,481 votes Against.
- Proposal 2 (Reverse Stock Split): 71,971,946 votes For; 8,230,746 votes Against.
- Proposal 3 (Post-Merger Warrants): 69,026,316 votes For; 6,662,323 votes Against.
- Proposal 4 (Combined Company Charter): 68,614,107 votes For; 7,040,014 votes Against.
- Proposal 6 (2024 Equity Incentive Plan): 71,363,789 votes For; 8,360,752 votes Against.
Proposal 5 consisted of eight non-binding advisory governance provisions, all of which received majority support.
Outlook, Risks, and Contingencies
Merger Timeline: The merger is anticipated to close on March 26, 2024, subject to the satisfaction or waiver of conditions. The combined company will commence trading under the new ticker "SER" on March 27, 2024.
Risks and Contingencies: The filing highlights significant risks that could prevent the merger from closing or impact future performance, including:
- Failure to satisfy merger conditions or termination of material agreements.
- Inability to obtain listing approval on the NYSE American.
- Risks associated with Serina's research and development programs, including clinical trial timing and regulatory approvals.
- Potential reduction in the combined company's cash balance and uncertainty regarding future financing needs.
- Dilution of existing AgeX shareholders due to the issuance of shares to Serina stockholders and the exercise of post-merger warrants.
Investor Verification Checklist
- Verify the effective time of the 1-for-35.17 reverse stock split and the new CUSIP number (00848H 207).
- Confirm the anticipated merger closing date of March 26, 2024, and the start of trading under ticker "SER" on March 27, 2024.
- Review the definitive proxy statement/prospectus for details on the Merger Agreement and the Side Letter with Juvenescence Limited.
- Assess the combined company's cash position and financing plans post-merger, as noted in the risk factors.
- Monitor the status of conditions precedent to the merger to ensure the transaction is not delayed or terminated.